Venrock Healthcare Capital Partners III, L.P. - Jan 30, 2025 Form 3 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
10%+ Owner
Signature
Venrock Healthcare Capital Partners III, L.P., By: VHCP Management III, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory
Stock symbol
KALV
Transactions as of
Jan 30, 2025
Transactions value $
$0
Form type
3
Date filed
2/3/2025, 07:39 PM
Previous filing
Feb 22, 2024
Next filing
Feb 11, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding KALV Common Stock 4.94M Jan 30, 2025 By Funds F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding KALV Pre-Funded Warrants (Right to Buy) Jan 30, 2025 Common Stock 656K $0.00 By Funds F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of (i) 1,079,452 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 107,980 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,755,341 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
F2 VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these shares. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these shares. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
F3 The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.
F4 Consists of (i) 172,394 pre-funded warrants held by VHCP3; (ii) 17,246 pre-funded warrants held by VHCP Co-3; and (iii) 466,098 pre-funded warrants held by VHCP EG.